Novo Nordisk's experimental hemophilia treatment, Mim8, significantly reduced bleeding in a large clinical trial.
Novo Nordisk's experimental hemophilia treatment, Mim8, reduced bleeding in a large clinical trial, showing potential for less frequent treatment for some patients. Monthly Mim8 doses significantly reduced bleeding compared to no prophylaxis and participants' previous treatments, with 95% of patients needing no extra treatment. This could challenge rivals like Roche's Hemlibra.
May 13, 2024
6 Articles